Company intelligence / Profile preview

AVAVA

Waltham, Massachusetts, United Statesavavaskin.com ↗

Ownership: Private
Development stage: Commercial

Overview

AVAVA’s Focal Point Technology™ has received FDA clearance to treat benign pigmented lesions and acne scarring in all Fitzpatrick skin types. Clinical results show consistent improvement in acne scarring across diverse patient populations with minimal downtime. The technology delivers high-energy treatments precisely into the skin while sparing surrounding tissue, addressing long-standing gaps in safe treatment options for all skin tones.[4][5]

Therapeutic areas: Dermatology
Modalities: Device (energy-based laser)Non-invasive medical device therapyAI-enabled imaging system (as part of the platform)
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

MIRIA

Commercial

Indications: Skin revitalization

Partnerships

Jeisys Medical, Inc. (strategic partner/investor)

Beyond the preview

Go deeper on AVAVA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AVAVA.

Explore the full profile